IMCERA SHARE REPURCHASE RESUMED
IMCERA SHARE REPURCHASE RESUMED NORTHBROOK, Ill., Feb. 20 /PRNewswire/ -- IMCERA Group Inc.
(NYSE: IMA) announced today that it has resumed repurchase of its common stock on the open market, as part of its stock repurchase authorization.
"Purchase of our own stock is one of the various investment opportunities to which we give continuing attention," said M. Blake Ingle, IMCERA president and chief operating officer. "Repurchase at this time reaffirms our belief in the long-term prospects of the company, and it will enhance shareholder value." IMCERA's board of directors reinstated IMCERA's repurchase authorization program last October. It had been suspended last April due to a common stock equity offering that was completed last year. There are currently 14.4 million shares remaining in the repurchase authorization. A Fortune 300 company with net sales of more than $1.6 billion in fiscal 1991, IMCERA provides human and animal health care products and specialty chemicals through its three international, technology-based businesses -- Mallinckrodt Medical of St. Louis; Mallinckrodt Specialty Chemicals of Chesterfield, Missouri; and Pitman-Moore of Lake Forest, Ill. -0- 2/20/92 /CONTACT: Dave Prichard of IMCERA, 708-205-2270/ (IMA) CO: IMCERA Group Inc. ST: Illinois IN: CHM SU:
KD -- NY094 -- 1149 02/20/92 17:24 EST
|Printer friendly Cite/link Email Feedback|
|Date:||Feb 20, 1992|
|Previous Article:||UNIVERSAL INTERNATIONAL ANNOUNCES FOURTH QUARTER RECORD REVENUES AND EARNINGS; ANNUAL RECORDS ARE ALSO SET IN 1991|
|Next Article:||INDUSTRY URGES VRA EXTENSION FOR SPECIALTY STEEL|